What is holding back the development of antiviral metallodrugs? A literature overview and implications for SARS-CoV-2 therapeutics and future viral outbreaks

In light of the Covid-19 outbreak, this review brings together historical and current literature efforts towards the development of antiviral metallodrugs. Classical compounds such as CTC-96 and auranofin are discussed in depth, as pillars for future metallodrug development. From the recent literatu...

Full description

Saved in:
Bibliographic Details
Published in:Dalton transactions : an international journal of inorganic chemistry 2020-11, Vol.49 (45), p.164-1633
Main Authors: de Paiva, Raphael E. F, Marçal Neto, Antônio, Santos, Igor A, Jardim, Ana C. G, Corbi, Pedro P, Bergamini, Fernando R. G
Format: Article
Language:English
Subjects:
Animals
Antiviral Agents - pharmacology
Antiviral Agents - therapeutic use
Betacoronavirus
Biomolecules
Coordination Complexes - pharmacology
Coordination Complexes - therapeutic use
Coordination compounds
Coronavirus Infections - drug therapy
Coronavirus Infections - epidemiology
COVID-19
Disease Outbreaks
Humans
Organometallic Compounds - pharmacology
Organometallic Compounds - therapeutic use
Outbreaks
Pandemics
Pneumonia, Viral - drug therapy
Pneumonia, Viral - epidemiology
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Viral diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In light of the Covid-19 outbreak, this review brings together historical and current literature efforts towards the development of antiviral metallodrugs. Classical compounds such as CTC-96 and auranofin are discussed in depth, as pillars for future metallodrug development. From the recent literature, both cell-based results and biophysical assays against potential viral biomolecule targets are summarized here. The comprehension of the biomolecular targets and their interactions with coordination compounds are emphasized as fundamental strategies that will foment further development of metal-based antivirals. We also discuss other possible and unexplored methods for unveiling metallodrug interactions with biomolecules related to viral replication and highlight the specific challenges involved in the development of antiviral metallodrugs. Despite a significative classical literature, metallodrugs have struggled to reach clinical practice. In light of the COVID-19 outbreak, this review aims at further encouraging and promoting the development of metallodrugs as viable antiviral agents.
ISSN:1477-9226
1477-9234
DOI:10.1039/d0dt02478c